Abzena, an end-to-end integrated contract development and manufacturing organisation (CDMO) for complex biologics and bioconjugates, announced on Tuesday it has been named a leader in the Frost Radar Report for Antibody-Drug Conjugate (ADC) CDMOs.

Frost & Sullivan recognised Abzena as a technology-forward CDMO, citing its proprietary ThioBridge platform, fully integrated service model, and deep scientific expertise as key differentiators in an increasingly competitive CDMO landscape, the company said.

Unmesh Patel, vice president, Healthcare & Life Sciences at Frost & Sullivan, said: "What sets Abzena apart is not just technology, but integration. From antibody discovery to GMP biologics manufacturing and high-potency bioconjugation, the company eliminates tech-transfer risk and compresses timelines, operating as a seamless extension of its clients' development teams."